![](https://investorshub.advfn.com/uicon/40536.png?cb=1561902029)
Saturday, May 11, 2019 6:06:55 PM
PHOENIX, July 6, 2018 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) announced today initiation of a program aimed at treating cancer associated wasting, through the in-licensing of patent application #15/814284 entitled "Treatment of Cachexia Using Stem Cells and Products Thereof".
Recently the Company announced data that the AmnioStem™ stem cell was superior to other stem cell types at reducing inflammatory mediators, including TNF-alpha1. It is well known that inflammatory mediators generated by cancer have a pivotal contribution to cancer associated weight loss, formally termed "cachexia". The Company believes that through suppression of inflammatory mediators, as well as direct anticancer effect of amniotic fluid stem cells2,3 that AmnioStemTM may provide value in the treatment of advanced cancer patients.
Cachexia is a very severe complication of cancer: weight loss during treatment is associated with more side effects of chemotherapy, fewer cycles of chemotherapy, a lower response to therapy, and even decreased survival. It is estimated that more than 20% of cancer patients die due to cachexia, and more than 50% of patients die with cachexia4.
"One of the most horrific aspects of having cancer is associated cachexia, which to date is not a major focus of research for the Pharmaceutical and Biotechnology industry. I strongly support the innovative approach that Creative Medical Technology Holdings is taking at dealing with this terrible condition," said Santosh Kesari, MD, PhD Chair and Professor of Department of Translational Neurosciences and Neurotherapeutics at Pacific Neuroscience Institute and John Wayne Cancer Institute at Providence Saint John's Health Center in Santa Monica, CA.
"We are confident that once we have completed Phase I clinical trials to demonstrate human safety of this cell, we will be well positioned to allow access to end stage cancer patients under the Right to Try law," said Thomas Ichim, Ph.D, Chief Scientific Officer and Cofounder of Creative Medical Technology Holdings.
On May 30th, 2018 President Trump signed the Right to Try law, which allows access to experimental medicines to patients suffering from end stage conditions for which no effective treatment is available. After signing the law, President Trump said the following, "With the Right to Try law I'm signing today, patients with life-threatening illnesses will finally have access to experimental treatments that could improve or even cure their conditions. These are experimental treatments and products that have shown great promise, and we weren't able to use them before. Now we can use them. And oftentimes they're going to be very successful. It's an incredible thing."
"I am very excited at the prospect of utilizing our patented AmnioStemTM technology to approach the terrible problem of cancer cachexia from a completely novel angle. This approach, if successful, will buy cancer patients time, time which could bridge them to new therapies and thus give them a new lease on life," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings.
Recent CELZ News
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 08:10:25 PM
- Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program • GlobeNewswire Inc. • 07/24/2024 01:00:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • GlobeNewswire Inc. • 07/10/2024 12:30:00 PM
- Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin • GlobeNewswire Inc. • 06/24/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/05/2024 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
- Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain • PR Newswire (US) • 10/10/2023 12:00:00 PM
- Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain • PR Newswire (US) • 09/19/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:45:38 PM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM